Nanjing Leads Biolabs Co., Ltd. (HKG:9887)

Market Cap	14.52B
Revenue (ttm)	n/a
Net Income (ttm)	-310.94M
Shares Out	193.36M
EPS (ttm)	-2.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,104,382
Average Volume	3,925,624
Open	69.35
Previous Close	75.10
Day's Range	69.35 - 75.50
52-Week Range	63.20 - 83.60
Beta	n/a
RSI	49.88
Earnings Date	n/a

About Nanjing Leads Biolabs

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma, as well as LBL-034, LBL-033, and LBL-007. In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinica...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 195
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9887

Financial Performance

Financial numbers in CNY